Kaplan Fox Announces $190 Million Settlement with Pfizer, Inc. and Warner-Lambert Co.

April 21, 2014

NEW YORK, April 21, 2014 /PRNewswire/ — Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) announces a $190 Million settlement, subject to court approval, with Pfizer, Inc. and Warner-Lambert Co. (“Defendants”) in In re Neurontin Antitrust Litigation, No. 02-1390, pending in the District of New Jersey.

Kaplan Fox serves as one of two co-lead counsel representing a class of direct purchasers of Neurontin from Defendants between December 11, 2002 and August 31, 2008 and who purchased generic Gabapentin, alleging that Defendants’ delayed the market entry of generic competitors, forcing class members to pay artificially inflated prices for Neurontin and its generic equivalents, by among other things, repeated filing of sham patent suits and illegal off-label promotion.

You may contact the following Kaplan Fox attorneys about the case and the settlement at (212) 687-1980:

Richard J. Kilsheimer: rkilsheimer@kaplanfox.com
Robert N. Kaplan: rkaplan@kaplanfox.com

SOURCE Kaplan Fox & Kilsheimer LLP

Source: PR Newswire

comments powered by Disqus